TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
SSY Group ( (HK:2005) ) just unveiled an announcement.
SSY Group Limited has announced that its Indocyanine Green product has received approval from China’s National Medical Products Administration for registration as a bulk drug. This development allows the product to be used for diagnosing liver diseases and choroidal angiography, potentially enhancing the company’s market presence and offering new diagnostic solutions.
The most recent analyst rating on (HK:2005) stock is a Buy with a HK$3.50 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of medical products. The company is involved in creating drugs for various medical applications, with a market focus on China.
Average Trading Volume: 14,245,329
Technical Sentiment Signal: Hold
Current Market Cap: HK$9.59B
See more data about 2005 stock on TipRanks’ Stock Analysis page.